Source:http://linkedlifedata.com/resource/pubmed/id/12384552
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
20
|
pubmed:dateCreated |
2002-10-17
|
pubmed:abstractText |
Tumor cells maintain an especially high glycolytic rate to supply the anabolic precursors essential for de novo nucleotide synthesis. We recently cloned an inducible isozyme of 6-phosphofructo-2 kinase (iPFK-2) that bears an oncogene-like regulatory element in its mRNA and functions to produce fructose-2,6-bisphosphate, which is a powerful allosteric activator of glycolysis. Rapidly proliferating cancer cells constitutively express iPFK-2 in vitro, and inhibition of iPFK-2 expression decreases tumor growth in experimental animal models. We report herein that the expression of iPFK-2 mRNA and protein, as assessed by in situ hybridization and immunohistochemistry, is increased in many human cancers when compared with corresponding normal tissues. In particular, iPFK-2 expression was found to be markedly elevated in multiple aggressive primary neoplasms, including colon, breast, ovarian, and thyroid carcinomas. iPFK-2 mRNA and protein expression were induced by hypoxia in cultured human colon adenocarcinoma cells, and an examination of normal lung fibroblasts showed that iPFK-2 and fructose-2,6-bisphosphate levels increased specifically during the S phase of the cell cycle. These data indicate that iPFK-2 is abundantly expressed in human tumors in situ and may serve as an essential regulator of glycolysis during cell cycle progression and growth in an hypoxic microenvironment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/PFKFB3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphofructokinase-2,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5881-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12384552-Cell Hypoxia,
pubmed-meshheading:12384552-DNA, Neoplasm,
pubmed-meshheading:12384552-Enzyme Induction,
pubmed-meshheading:12384552-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:12384552-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:12384552-Humans,
pubmed-meshheading:12384552-Neoplasms,
pubmed-meshheading:12384552-Phosphofructokinase-2,
pubmed-meshheading:12384552-Protein Biosynthesis,
pubmed-meshheading:12384552-Proteins,
pubmed-meshheading:12384552-RNA, Messenger,
pubmed-meshheading:12384552-S Phase,
pubmed-meshheading:12384552-Up-Regulation
|
pubmed:year |
2002
|
pubmed:articleTitle |
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
|
pubmed:affiliation |
The Picower Institute for Medical Research NY, Manhasset, New York 10030, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|